{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:00:17Z","timestamp":1789596017376,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10072-021-05607-2","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T09:07:50Z","timestamp":1632388070000},"page":"2537-2544","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Safinamide improves sleep and daytime sleepiness in Parkinson\u2019s disease: results from the SAFINONMOTOR study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-5111","authenticated-orcid":false,"given":"Diego","family":"Santos Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iria","family":"Cabo L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Labandeira Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Y\u00e1\u00f1ez Ba\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria I.","family":"Cimas Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Paz Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Alonso Losada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Gonzalez Palm\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cores Bartolom\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mart\u00ednez Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"5607_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2217\/nmt.15.46","volume":"5","author":"M Fabbri","year":"2015","unstructured":"Fabbri M, Rosa MM, Abreu D, Ferreira JJ (2015) Clinical pharmacology review of safinamide for the treatment of Parkinson\u2019s disease. Neurodegener Dis Manag 5:481\u2013496","journal-title":"Neurodegener Dis Manag"},{"key":"5607_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2147\/DDDT.S77749","volume":"10","author":"F Stocchi","year":"2016","unstructured":"Stocchi F, Torti M (2016) Adjuvant therapies for Parkinson\u2019s disease: critical evaluation of safinamide. Drug Des Devel Ther 10:609\u2013618","journal-title":"Drug Des Devel Ther"},{"key":"5607_CR3","doi-asserted-by":"crossref","unstructured":"Borgohain R, Szasz J, Stanzione P, et al. Study 016 Investigators (2014) Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations. Mov Disord 29:229\u201337","DOI":"10.1002\/mds.25751"},{"key":"5607_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/mds.25961","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P et al (2014) Study 018 Investigators. Mov Disord 29:1273\u20131280","journal-title":"Mov Disord"},{"key":"5607_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.17925\/ENR.2015.10.01.15","volume":"10","author":"J Schnitker","year":"2015","unstructured":"Schnitker J, M\u00fcller T (2015) Meta-analysis of placebo-controlled clinical trials of safinamide and entacapone as add-on therapy to levodopa in the treatment of Parkinson\u2019s disease. Eur Neurol Rev 10:15\u201322","journal-title":"Eur Neurol Rev"},{"key":"5607_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10072-018-3628-3","volume":"40","author":"MLE Bianchi","year":"2019","unstructured":"Bianchi MLE, Riboldazzi G, Mauri M, Versino M (2019) Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson\u2019s disease. Neurol Sci 40:275\u2013279","journal-title":"Neurol Sci"},{"key":"5607_CR7","doi-asserted-by":"publisher","first-page":"E57","DOI":"10.3390\/brainsci11010057","volume":"11","author":"A G\u00f3mez-L\u00f3pez","year":"2021","unstructured":"G\u00f3mez-L\u00f3pez A, S\u00e1nchez-S\u00e1nchez A, Natera-Villalba E et al (2021) SURINPARK: Safinamide for urinary symptoms in Parkinson\u2019s disease. Brain Sci 11:E57","journal-title":"Brain Sci"},{"key":"5607_CR8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/brainsci11020232","volume":"11","author":"E Pe\u00f1a","year":"2021","unstructured":"Pe\u00f1a E, Borru\u00e9 C, Mata M et al (2021) Impact of SAfinamide on Depressive Symptoms in Parkinson\u2019s Disease Patients (SADness-PD Study): a multicenter retrospective study. Brain Sci 11:232","journal-title":"Brain Sci"},{"key":"5607_CR9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00702-020-02218-7","volume":"127","author":"C Geroin","year":"2020","unstructured":"Geroin C, Di Vico IA, Squintani G, Segatti A, Bovi T, Tinazzi M (2020) Effects of safinamide on pain in Parkinson\u2019s disease with motor fluctuations: an exploratory study. J Neural Transm (Vienna) 127:1143\u20131152","journal-title":"J Neural Transm (Vienna)"},{"key":"5607_CR10","doi-asserted-by":"publisher","unstructured":"Santos Garc\u00eda D, Labandeira Guerra C, Y\u00e1\u00f1ez Ba\u00f1a R et al (2021) Safinamide improves non-motor symptoms burden in Parkinson\u2019s disease: an open-label prospective study. Brain Sci 11(3):316. https:\/\/doi.org\/10.3390\/brainsci11030316","DOI":"10.3390\/brainsci11030316"},{"key":"5607_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.parkreldis.2018.06.033","volume":"57","author":"C Liguori","year":"2018","unstructured":"Liguori C, Stefani A, Ruffini R, Mercuri NB, Pierantozzi M (2018) Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson\u2019s disease patients: a validated questionnaires-controlled study. Parkinsonism Relat Disord 57:80\u201381","journal-title":"Parkinsonism Relat Disord"},{"key":"5607_CR12","first-page":"165","volume":"39","author":"SE Daniel","year":"1993","unstructured":"Daniel SE, Lees AJ (1993) Parkinson\u2019s Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 39:165\u2013172","journal-title":"J Neural Transm Suppl"},{"key":"5607_CR13","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/mds.21844","volume":"22","author":"B Dubois","year":"2007","unstructured":"Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA et al (2007) Diagnostic procedures for Parkinson\u2019s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314\u20132324","journal-title":"Mov Disord"},{"key":"5607_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540\u2013545","journal-title":"Sleep"},{"key":"5607_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193\u2013213","journal-title":"Psychiatry Res"},{"key":"5607_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/mdc3.12921","volume":"7","author":"S Schade","year":"2020","unstructured":"Schade S, Mollenhauer B, Trenkwalder C (2020) Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide. Mov Disord Clin Pract 7:343\u2013345","journal-title":"Mov Disord Clin Pract"},{"key":"5607_CR17","doi-asserted-by":"crossref","unstructured":"Rinaldi D, Sforza M, Assogna F, et al (2020) Safinamide improves executive functions in fluctuating Parkinson\u2019s disease patients: an exploratory study. J Neural Transm (Vienna)","DOI":"10.1007\/s00702-020-02259-y"},{"key":"5607_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/ene.14552","volume":"28","author":"F Stocchi","year":"2021","unstructured":"Stocchi F, Vacca L, Grassini P et al (2021) Overnight switch from rasagiline to safinamide in Parkinson\u2019s disease patients with motor fluctuations: a tolerability and safety study. Eur J Neurol 28:349\u2013354","journal-title":"Eur J Neurol"},{"key":"5607_CR19","unstructured":"Sforza MS, Pontieri FE, Rinaldi DR, Bianchini EB (2020) A pilot study on the shift from rasagiline to safinamide in fluctuating Parkinson\u2019s disease patients [abstract]. Mov Disord 35 (suppl 1)"},{"key":"5607_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jocn.2021.07.011","volume":"91","author":"M Plastino","year":"2021","unstructured":"Plastino M, Gorgone G, Fava A et al (2021) Effects of safinamide on REM sleep behavior disorder in Parkinson disease: a randomized, longitudinal, cross-over pilot study. J Clin Neurosci 91:306\u2013312","journal-title":"J Clin Neurosci"},{"key":"5607_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3233\/JPD-171143","volume":"7","author":"C Cattaneo","year":"2017","unstructured":"Cattaneo C, M\u00fcller T, Bonizzoni E, Lazzeri G, Kottakis I, Keywood C (2017) Long-term effects of safinamide on mood fluctuations in Parkinson\u2019s disease. J Parkinsons Dis 7:629\u2013634","journal-title":"J Parkinsons Dis"},{"key":"5607_CR22","doi-asserted-by":"crossref","unstructured":"Kurtis MM, Rodriguez-Blazquez C, Martinez-Martin P; ELEP Group (2013) Relationship between sleep disorders and other non-motor symptoms in Parkinson\u2019s disease. Parkinsonism Relat Disord 19:1152\u20135","DOI":"10.1016\/j.parkreldis.2013.07.026"},{"key":"5607_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jns.2013.07.005","volume":"332","author":"D Santos-Garc\u00eda","year":"2013","unstructured":"Santos-Garc\u00eda D, de la Fuente-Fern\u00e1ndez R (2013) Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson\u2019s disease. J Neurol Sci 332:136\u2013140","journal-title":"J Neurol Sci"},{"key":"5607_CR24","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/mds.28261","volume":"35","author":"D Santos-Garc\u00eda","year":"2020","unstructured":"Santos-Garc\u00eda D, Oreiro M, P\u00e9rez P et al (2020) Impact of coronavirus disease 2019 pandemic on Parkinson\u2019s disease: a cross-sectional survey of 568 Spanish patients. Mov Disord 35:1712\u20131716","journal-title":"Mov Disord"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05607-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-021-05607-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-021-05607-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T09:47:50Z","timestamp":1744192070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-021-05607-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["5607"],"URL":"https:\/\/doi.org\/10.1007\/s10072-021-05607-2","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]},"assertion":[{"value":"10 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Santos Garc\u00eda D. has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, Italfarmaco, and Teva. Cabo L\u00f3pez I. has received honoraria for educational presentations and advice service by Abbvie and Zambon and Bial. Labandeira Guerra C. has received honoraria for educational presentations and advice service by Abbvie, Italfarmaco, Zambon, and Bial. Y\u00e1\u00f1ez Ba\u00f1a R. has received honoraria for educational presentations by Teva, Bial, and Zambon. Cimas Hernando MI. has received honoraria for educational presentations and advice service by KRKA, Italfarmaco, Teva, Zambon, and Bial. Paz Gonz\u00e1lez JM. has received honoraria for educational presentations and\/or advice service by UCB Pharma, Lundbeck, KRKA, and Zambon. Alonso Losada M. has received honoraria for educational presentations and advice service by Zambon and Bial. Gonz\u00e1lez Palm\u00e1s MJ: None. Cores C. has received honoraria for educational presentations and advice service by Lundbeck and UCB Pharma. Mart\u00ednez Mir\u00f3 C: None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval from the Comit\u00e9 de \u00c9tica de la Investigaci\u00f3n Cl\u00ednica de Galicia from Spain (2018-052; 28\/FEB\/2019) was\u00a0obtained for the present study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}